Weight-loss drug Mounjaro is not value for money at current price, study shows

The National Centre for Pharmacoeconomics said it would only be value for money if the price was reduced by 73 per cent.
Weight-loss drug Mounjaro is not value for money at current price, study shows

Eva Osborne

A study has found that making the weight-loss drug Mounjaro available to public patients would not be value for money at the current price.

The cost per patient per year would range from €5,000 to €6,000, according to the National Centre for Pharmacoeconomics.

It said it would only be value for money if the price were reduced by 73 per cent.

Mounjaro helps people who have health conditions loose weight, by regulating blood sugars and making people feel fuller for longer.

More in this section